/

PTCT

PTC Therapeutics, Inc.Open

60.70−2.22 −3.54%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

62.64

Prev close

62.92

Day range

60.6362.75

52-week range

60.6390.87

Volume

109.78K0.10×

Mkt cap

5.07B

P/E ttm

—

Fwd P/E

25.61

EPS ttm

-0.6500

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−33.21%

Price Chart

Yahoo Finance · delayed

PTCTOct 13, 2026O 62.64H 62.75L 60.63C 60.69−2.22 (−3.54%)Vol 109.78K

SMA 5068.09
SMA 20071.67

1Y change −8.36% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PTCT PTC Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.72%
1 month: −8.12%
3 months: −22.25%
6 months: −16.87%
Year to date: −20.10%
1 year: −8.12%

Valuation & ownership

Market cap: 5.07B
Enterprise value: 6.04B
P/E (ttm): —
Forward P/E: 25.61
PEG ratio: —
Price / book: —
Price / sales (ttm): 5.02
EV / EBITDA: 35.28
EPS (ttm): -0.6500
EPS (forward): 2.37
Beta (5y monthly): 0.49
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 83.46M
Float: 73.69M
Short % of float: 14.89%
Short ratio (days): 7.61
Held by insiders: 7.31%
Held by institutions: 122.80%
Avg volume (3m): 1.14M
50-day average: 68.24
200-day average: 71.76
52-week change: −8.12%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 34.7
vs 50-day SMA: −10.86%
vs 200-day SMA: −15.32%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.49%
Realised vol (20d, ann.): 39.7%
From 52-week high: −33.21%
From 52-week low: +0.12%

ANR

Analyst Consensus

14 analysts

Consensus

Buy

1.71 on a 1 (strong buy) – 5 (sell) scale

Mean target

101.07

+66.52% implied

Low 70.00Median 101.00High 137.00

Recommendation trend

Now12 / 1 / 1
1m ago

DES

About PTC Therapeutics, Inc.

Yahoo Finance profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 991
Headquarters: Warren, NJ, United States
Website: ptcbio.com
Officers: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

SEAS

Seasonality · PTCT

2013–2026 · monthly returns

Strongest month Nov +13.45%Weakest month Oct −7.51%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.6	-9.7	-0.1	-4.5	13.5	10.5	-16.6	2.2	-6.8	-6.3			−20.1%
2025	1.6	20.4	-7.8	-2.2	-2.6	0.7	6.7	-5.3	24.4	11.3	25.9	-11.7	+68.3%
2024	-5.3	8.0	3.2	10.5	13.1	-15.9	10.7	4.3	5.0	7.6	9.9	2.9	+63.8%
2023	20.2	-4.8	10.9	13.8	-23.9	-3.1	-0.8	-2.1	-43.3	-16.3	22.8	19.7	−27.8%
2022	1.0	-12.7	6.2	-5.3	-16.9	36.4	8.7	14.7	0.5	-24.7	9.7	-8.0	−4.2%
2021	-5.3	-1.2	-17.1	-13.0	-4.7	7.6	-9.3	13.9	-14.8	1.9	-2.0	7.2	−34.7%
2020	7.2	6.5	-18.7	14.1	-0.4	0.1	-8.7	6.7	-5.4	11.6	19.9	-2.5	+27.1%
2019	-9.3	11.0	9.0	-0.6	7.2	12.2	7.0	-7.5	-24.1	20.9	14.8	2.3	+39.9%
2018	57.6	-2.1	5.1	2.5	22.3	-0.5	12.9	9.6	12.6	-18.0	-7.8	-3.4	+105.8%
2017	20.1	4.0	-27.8	23.5	3.1	46.3	12.5	0.6	-3.6	-6.3	-14.9	4.6	+52.9%
2016	-26.5	-66.5	-19.3	15.2	10.0	-14.0	-15.0	37.5	70.6	-55.7	79.4	-2.1	−66.3%
2015	6.1	29.9	-14.7	-3.5	-1.1	-17.1	6.4	-25.4	-30.1	-6.9	20.8	7.9	−37.4%
2014	53.6	20.3	-16.6	-25.2	21.3	10.2	1.1	19.8	39.0	-7.1	9.5	15.7	+205.1%
2013							4.4	14.6	19.6	-15.9	-13.1	8.3	+13.1%

INSD

Insider Activity · PTCT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

205.8K shares

Sells, 6 months

290.2K shares

Net shares

−84.4K

Net change in insider shares

−1.40%

Date	Insider	Transaction	Shares	Value
Oct 5, 2026	Boulding Mark ElliottOfficer	Sale at price 64.03 - 64.16 per share.	2.1K	$132.79K
Oct 5, 2026	Boulding Mark ElliottOfficer	Conversion of Exercise of derivative security at price 39.42 per share.	2.1K	$81.72K
Sep 9, 2026	Schmertzler MichaelDirector	Sale at price 67.34 - 68.67 per share.	20K	$1.35M
Aug 26, 2026	Schmertzler MichaelDirector	Sale at price 71.55 - 73.18 per share.	25K	$1.81M
Aug 19, 2026	Schmertzler MichaelDirector	Sale at price 70.78 - 73.67 per share.	25K	$1.81M
Aug 16, 2026	Boulding Mark ElliottOfficer	Sale at price 72.39 - 72.90 per share.	2.8K	$204.13K
Aug 16, 2026	Boulding Mark ElliottOfficer	Conversion of Exercise of derivative security at price 25.69 per share.	2.8K	$72.27K
Aug 3, 2026	Klein Matthew BChief Executive Officer	Sale at price 68.57 per share.	10.3K	$705.72K
Jul 13, 2026	Gravier PierreChief Financial Officer	Sale at price 80.35 per share.	3.5K	$280.74K
Jul 8, 2026	Almstead Neil GregoryChief Technology Officer	Sale at price 90.25 per share.	2.5K	$222.38K
Jul 8, 2026	Almstead Neil GregoryChief Technology Officer	Conversion of Exercise of derivative security at price 46.54 per share.	2.5K	$114.67K
Jul 8, 2026	Smith Mary LDirector	Sale at price 90.00 per share.	15.8K	$1.43M
Jul 8, 2026	Smith Mary LDirector	Conversion of Exercise of derivative security at price 42.95 per share.	15.8K	$680.07K
Jul 6, 2026	Almstead Neil GregoryChief Technology Officer	Sale at price 85.28 - 89.44 per share.	46.8K	$4.09M
Jul 6, 2026	Almstead Neil GregoryChief Technology Officer	Conversion of Exercise of derivative security at price 38.10 - 39.42 per share.	46.8K	$1.82M
Jul 5, 2026	Boulding Mark ElliottOfficer	Sale at price 83.10 - 86.38 per share.	5.1K	$432.12K
Jul 5, 2026	Boulding Mark ElliottOfficer	Conversion of Exercise of derivative security at price 39.42 - 46.54 per share.	5.1K	$220.24K
Jun 25, 2026	Almstead Neil GregoryChief Technology Officer	Sale at price 85.23 - 85.26 per share.	8.1K	$693.15K
Jun 25, 2026	Almstead Neil GregoryChief Technology Officer	Conversion of Exercise of derivative security at price 38.10 per share.	8.1K	$309.75K
Jun 24, 2026	Almstead Neil GregoryOfficer	Sale at price 85.01 - 87.00 per share.	26.3K	$2.25M

13F

Investors Holding PTCT

latest 13F filings of 29 followed managers

Investors holding PTCT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$59.0M	0.08%	723.50K	+36%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PTCT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PTCT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About PTC Therapeutics, Inc.

Seasonality · PTCT

Insider Activity · PTCT

Congress Trades · PTCT

Investors Holding PTCT

Investors Holding PTCT

Congress Trades · PTCT

Seasonality · PTCT

Insider Activity · PTCT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About PTC Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News